Abstract
Next Generation Sequencing (NGS) is revolutionizing the study of “omics” (e.g., genomics, transcriptomics, methylomics, etc). The sequencing cost has gone down tremendously and thereby allowing most of the methods to deviate from microarrays and traditional Sanger sequencing. Illumina has the highest market share in NGS followed by Thermofisher Scientific, Roche and Pacific Biosciences. They currently sell the following instruments: HiSeqX series, HiSeq series, MiSeq, NextSeq and MiniSeq. With the arrival of HiSeqX, Illumina projects that the cost per Gigabase has gone down from $100,000,000 in the year 2000 to $1-10 in year 2014. Read-length, run time bacterial genome sequencing and maximum throughput on different platforms is reviewed in Van Djik et al., and the number of applications that can be performed using NGS is increasing every day. They can be categorized into three areas as described below.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Next Generation Sequencing & Applications
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
